WO2001060387A1 - Agent antiresistance multiple aux medicaments - Google Patents

Agent antiresistance multiple aux medicaments Download PDF

Info

Publication number
WO2001060387A1
WO2001060387A1 PCT/US2001/004920 US0104920W WO0160387A1 WO 2001060387 A1 WO2001060387 A1 WO 2001060387A1 US 0104920 W US0104920 W US 0104920W WO 0160387 A1 WO0160387 A1 WO 0160387A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
pgp
composition
formula
joined
Prior art date
Application number
PCT/US2001/004920
Other languages
English (en)
Inventor
Merritt Andrus
Timothy Turner
John Prince
Original Assignee
Brigham Young University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham Young University filed Critical Brigham Young University
Priority to EP01910773A priority Critical patent/EP1272202A1/fr
Priority to AU2001238344A priority patent/AU2001238344A1/en
Publication of WO2001060387A1 publication Critical patent/WO2001060387A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un agent antirésistance multiple aux médicaments (anti-MDR). L'agent, qui est polyvalent, possède deux ou davantage de domaines de liaison espacés pour inhiber efficacement l'activité de résistance multiple aux médicaments de PgP. L'agent anti-MDR renferme le composé d'origine naturelle (-)-stipiamide. L'agent anti-MDR peut être un homodimère renfermant napthyl-DHS. L'homodimère incorpore deux domaines napthyl-DHS réunis par une série d'espaceurs d'éthylène glycol assemblés. L'invention concerne aussi un procédé permettant de lutter contre la MDR dans une cellule humaine, par l'administration de l'agent décrit dans cette l'invention. Quand Pgp est mis en contact avec cet agent, l'activité d'ATPase de Pgp est réduite de manière importante ainsi que l'affinité de liaison de Pgp pour ses substrats connus.
PCT/US2001/004920 2000-02-16 2001-02-16 Agent antiresistance multiple aux medicaments WO2001060387A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01910773A EP1272202A1 (fr) 2000-02-16 2001-02-16 Agent antiresistance multiple aux medicaments
AU2001238344A AU2001238344A1 (en) 2000-02-16 2001-02-16 Multiple drug resistance reversal agent

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18290000P 2000-02-16 2000-02-16
US60/182,900 2000-02-16

Publications (1)

Publication Number Publication Date
WO2001060387A1 true WO2001060387A1 (fr) 2001-08-23

Family

ID=22670535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/004920 WO2001060387A1 (fr) 2000-02-16 2001-02-16 Agent antiresistance multiple aux medicaments

Country Status (3)

Country Link
EP (1) EP1272202A1 (fr)
AU (1) AU2001238344A1 (fr)
WO (1) WO2001060387A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1238654A2 (fr) * 2001-03-06 2002-09-11 Kao Corporation Composition pour application externe contenant une diamide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KANAI M. ET AL.: "Varying the Size of Multivalent Ligands: The Dependence of Concanavalin A Binding on Neoglycopolymer Length", J. AM. CHEM. SOC., vol. 119, 1997, pages 9931 - 9932, XP002942857 *
KIM ET AL.: "Isolation and Structural Elucidation of Stipiamide, A new Antibiotic Effective to Multidrug-Resistant cancer cells", J. OF ANTIBIOTICS, vol. 44, no. 5, 1991, pages 553 - 556, XP002942856 *
SUNDRAM U. N. ET AL.: "Novel Vancomycin Dimers with Activity against Vancomycin-Resistant Enterococci", J. AM. CHEM. SOC., vol. 118, 1996, pages 13107 - 13108, XP002942858 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1238654A2 (fr) * 2001-03-06 2002-09-11 Kao Corporation Composition pour application externe contenant une diamide
EP1238654A3 (fr) * 2001-03-06 2004-01-14 Kao Corporation Composition pour application externe contenant une diamide
US7087646B2 (en) 2001-03-06 2006-08-08 Kao Corporation Composition for external application
EP1803439A3 (fr) * 2001-03-06 2008-06-11 Kao Corporation Composition pour application externe contenant un diamide
US7528171B2 (en) 2001-03-06 2009-05-05 Kao Corporation Composition for external application
US7550135B2 (en) 2001-03-06 2009-06-23 Kao Corporation Composition for external application

Also Published As

Publication number Publication date
EP1272202A1 (fr) 2003-01-08
AU2001238344A1 (en) 2001-08-27

Similar Documents

Publication Publication Date Title
US20240067756A1 (en) Chimeric small molecules for the recruitment of antibodies to cancer cells
EP2291659B1 (fr) Petites molécules chimériques pour le recrutement d'anticorps dirigés contre des cellules cancéreuses
JP6190025B2 (ja) ジグリシドエーテル誘導体治療剤およびその使用方法
US20220111060A1 (en) Synthetic antibody mimetic compounds (syams) targeting cancer, especially prostate cancer
JP2020526519A (ja) 分枝多官能性マクロモノマーおよび関連ポリマーならびにそれらの使用
TW201938149A (zh) 用於治療癌症的選擇性組蛋白去乙醯酶3 (hdac3)抑制劑及免疫治療劑之組合
CN110090308B (zh) 制备偶联物的方法
KR20150053257A (ko) 플루오르화 2-아미노-4-(벤질아미노)페닐카르바메이트 유도체
EP3774986A1 (fr) Promédicaments à brosse et leurs utilisations
JPWO2005079845A1 (ja) 片頭痛予防薬
CN117069793A (zh) 双功能接头化合物、抗体药物偶联物及其制备方法和应用
CN111542324B (zh) 细胞毒性剂及其偶联物、其制备方法及用途
US20030008922A1 (en) Multiple drug resistance reversal agent
EP1272202A1 (fr) Agent antiresistance multiple aux medicaments
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
AU2012311183A1 (en) N- substituted benzenepropanamide and benzenepropenamide for use in the prevention or the treatment of affective disorders
EA006852B1 (ru) Бис(n,n'-бис(2-галоэтил)амино)фосфороамидаты в качестве противоопухолевых агентов

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10203724

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001910773

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001910773

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001910773

Country of ref document: EP